

New Products - Forxiga

Forxiga (**dapagliflozin propanediol monohydrate**) is an orally active inhibitor of the human renal sodium glucose cotransporter 2 (SGLT2), with nanomolar potency that improves glycemic control in patients with type 2 diabetes mellitus by reducing renal glucose reabsorption leading to urinary glucose excretion (glucuresis). Forxiga is indicated in type 2 diabetes (with diet, exercise) as: monotherapy when metformin not tolerated; initial combination with metformin when diet, exercise inadequate and poor response to metformin expected and as an add-on combination with metformin, sulfonylurea or insulin (+/- metformin and/or sulfonylurea) when diet, exercise, existing therapy inadequate. It is contraindicated in moderate to severe renal impairment. Forxiga is available as 10 mg tablets in packs of 7's and 28's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.